2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differences
2016
Guanfacine alters the effect of stress and smoking on heart rate variability in regular daily smokers
Verplaetse TL, Smith PH, Smith KM, Oberleitner LM, McKee SA. Guanfacine alters the effect of stress and smoking on heart rate variability in regular daily smokers. Psychopharmacology 2016, 234: 805-813. PMID: 28028603, PMCID: PMC5309140, DOI: 10.1007/s00213-016-4517-1.Peer-Reviewed Original ResearchConceptsHeart rate variabilityRegular daily smokersEffects of guanfacineSmoking lapse behaviorHF-HRVPlacebo groupDaily smokersRate variabilitySmoking-related decreaseΑ2A-adrenergic agonistAd libitum smokingAd lib smokingHigh-frequency heart rate variabilityEffects of stressStress imageryNoradrenergic targetsVagal activityParent studySmokingGuanfacineTonic levelsPhasic changesNeutral imagery conditionsPotential mechanismsImportant marker